EE47 Cost Per Recurrence-Free Survivor (CPRS) and Cost Per Recurrence-Free Life Month (CPRLM) of Adjuvant Nivolumab (NIVO) Versus Pembrolizumab (PEMBRO) Among Patients With Resected Stage IIB/IIC Melanoma
Abstract
Authors
JM Davis S Srinivasan EX Du C Xu J Linton K Betts K Shelley